Chardan Capital Markets analyst Keay Nakae raised the price target on ProQR Therapeutics N.V. (NASDAQ: PRQR) to $21.00 (from $9.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

ProQR (PRQR) Prices 5.75M Share Common Offering at $15.75/ShSeptember 7, 2018 5:45 AM ProQR (PRQR) Announces Proposed $75M Public Share OfferingSeptember 5, 2018 4:02 PM ProQR (PRQR) Surges Amid Positive 1/2 trial of QR-110, Plans to Progress to Pivotal Phase 2/3 TrialSeptember 5, 2018 9:14 AM Form 6-K ProQR Therapeutics N.V. For: Sep 05September 5, 2018 8:16 AM ProQR (PRQR) Reports Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients; Plans to Start a Phase 2/3 Pivotal TrialSeptember 5, 2018 5:49 AM